|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kerr J, Anderson C and Lippman SM:
Physical activity, sedentary behaviour, diet, and cancer: An update
and emerging new evidence. Lancet Oncol. 18:e457–e471.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Argilés G, Tabernero J, Labianca R,
Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P,
Yoshino T, Taieb J, et al: Localised colon cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 31:1291–1305. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Glynne-Jones R, Wyrwicz L, Tiret E, Brown
G, Rödel C, Cervantes A and Arnold D: ESMO Guidelines Committee.
Rectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 28 (Suppl 4):iv22–iv40.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
van Cutsem E, Nordlinger B and Cervantes
A: ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO
clinical practice guidelines for treatment. Ann Oncol. 21 (Suppl
5):v93–v97. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Boussios S, Ozturk MA, Moschetta M,
Karathanasi A, Zakynthinakis-Kyriakou N, Katsanos KH, Christodoulou
DK and Pavlidis N: The developing story of predictive biomarkers in
colorectal cancer. J Pers Med. 9(12)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Moertel CG, Fleming TR, Macdonald JS,
Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA,
Tormey DC and Glick JH: Levamisole and fluorouracil for adjuvant
therapy of resected colon carcinoma. N Engl J Med. 322:352–358.
1990.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Punt CJA, Koopman M and Vermeulen L: From
tumour heterogeneity to advances in precision treatment of
colorectal cancer. Nat Rev Clin Oncol. 14:235–246. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bahadoer RR, Dijkstra EA, van Etten B,
Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID,
Beets-Dan RGH, Blomqvist L, et al: Short-course radiotherapy
followed by chemotherapy before total mesorectal excision (TME)
versus preoperative chemoradiotherapy, TME, and optional adjuvant
chemotherapy in locally advanced rectal cancer (RAPIDO): A
randomised, open-label, phase 3 trial. Lancet Oncol. 22:29–42.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Conroy T, Lamficheck N, Etienne PL, Rio E,
Francois E, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O,
Gargot D, et al: Total neoadjuvant therapy with mFOLFIRINOX versus
preoperative chemoradiation in patients with locally advanced
rectal cancer: Final results of PRODIGE 23 phase III trial, a
UNICANCER GI trial. J Clin Oncol. 38(S4007)2020.
|
|
11
|
Ebert MPA, Tänzer M, Balluff B,
Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day
C, Rosenberg R, Reinacher-Schick AC, et al: TFAP2E-DKK4 and
chemoresistance in colorectal cancer. N Engl J Med. 366:44–53.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Friedman AA, Letai A, Fisher DE and
Flaherty KT: Precision medicine for cancer with next-generation
functional diagnostics. Nat Rev Cancer. 15:747–756. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Garnett MJ, Edelman EJ, Heidorn SJ,
Greenman CD, Dastur A, Lau KW, Greninger P, Thompson R, Luo X,
Soares J, et al: Systematic identification of genomic markers of
drug sensitivity in cancer cells. Nature. 483:570–575.
2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang L, Zhou S, Zhang W, Wang J, Wang M,
Hu X, Liu F, Zhang Y, Jiang B and Yuan H: Circulating tumor cells
as an independent prognostic factor in advanced colorectal cancer:
A retrospective study in 121 patients. Int J Colorectal Dis.
34:589–597. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yang C, Chen F, Wang S and Xiong B:
Circulating tumor cells in gastrointestinal cancers: Current status
and future perspectives. Front Oncol. 9(1427)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kapeleris J, Kulasinghe A, Warkiani ME,
Vela I, Kenny L, O'Byrne K and Punyadeera C: The prognostic role of
circulating tumor cells (CTCs) in lung cancer. Front Oncol.
8(311)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Banys-Paluchowski M, Krawczyk N and Fehm
T: Potential role of circulating tumor cell detection and
monitoring in breast cancer: A review of current evidence. Front
Oncol. 6(255)2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xun Y, Cao Q, Zhang J, Guan B and Wang M:
Clinicopathological and prognostic significance of circulating
tumor cells in head and neck squamous cell carcinoma: A systematic
review and meta-analysis. Oral Oncol. 104(104638)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Schlüter C, Duchrow M, Wohlenberg C,
Becker MH, Key G, Flad HD and Gerdes J: The cell
proliferation-associated antigen of antibody Ki-67: A very large,
ubiquitous nuclear protein with numerous repeated elements,
representing a new kind of cell cycle-maintaining proteins. J Cell
Biol. 123:513–522. 1993.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Pizon M, Schott DS, Pachmann U and
Pachmann K: B7-H3 on circulating epithelial tumor cells correlates
with the proliferation marker, Ki-67, and may be associated with
the aggressiveness of tumors in breast cancer patients. Int J
Oncol. 53:2289–2299. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Union for International Cancer Control
(UICC): Colon and Rectum. In: TNM classification of malignant
tumours. Brierley J, Gospodarowicz MK and Wittekind C (eds) John
Wiley & Sons Ltd., Chichester, pp73-76, 2017.
|
|
22
|
Pox C: Update der S3-leitlinie zum
kolorektalen karzinom. Best Pract Onkol. 13:254–262. 2018.(In
German).
|
|
23
|
Dworak O, Keilholz L and Hoffmann A:
Pathological features of rectal cancer after preoperative
radiochemotherapy. Int J Colorectal Dis. 12:19–23. 1997.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pachmann K, Willecke-Hochmuth R, Schneider
K and Kaatz M: Circulating epithelial tumor cells as a prognostic
tool for malignant melanoma. Melanoma Res. 28:37–43.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Krebs MG, Sloane R, Priest L, Lancashire
L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G,
et al: Evaluation and prognostic significance of circulating tumor
cells in patients with non-small-cell lung cancer. J Clin Oncol.
29:1556–1563. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rahbari NN, Aigner M, Thorlund K, Mollberg
N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M and Weitz
J: Meta-analysis shows that detection of circulating tumor cells
indicates poor prognosis in patients with colorectal cancer.
Gastroenterology. 138:1714–1726. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239.
2007.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lara O, Tong X, Zborowski M and Chalmers
JJ: Enrichment of rare cancer cells through depletion of normal
cells using density and flow-through, immunomagnetic cell
separation. Exp Hematol. 32:891–904. 2004.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Park JM, Lee JY, Lee JG, Jeong H, Oh JM,
Kim YJ, Park D, Kim MS, Lee HJ, Oh JH, et al: Highly efficient
assay of circulating tumor cells by selective sedimentation with a
density gradient medium and microfiltration from whole blood. Anal
Chem. 84:7400–7407. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pachmann K: Current and potential use of
MAINTRAC method for cancer diagnosis and prediction of metastasis.
Expert Rev Mol Diagn. 15:597–605. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Desitter I, Guerrouahen BS, Benali-Furet
N, Wechsler J, Jänne PA, Kuang Y, Yanagita M, Wang L, Berkowitz JA,
Distel RJ and Cayre YE: A new device for rapid isolation by size
and characterization of rare circulating tumor cells. Anticancer
Res. 31:427–441. 2011.PubMed/NCBI
|
|
32
|
Wang L, Balasubramanian P, Chen AP, Kummar
S, Evrard YA and Kinders RJ: Promise and limits of the cellSearch
platform for evaluating pharmacodynamics in circulating tumor
cells. Semin Oncol. 43:464–475. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cohen SJ, Punt CJA, Iannotti N, Saidman
BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller
MC, et al: Relationship of circulating tumor cells to tumor
response, progression-free survival, and overall survival in
patients with metastatic colorectal cancer. J Clin Oncol.
26:3213–3221. 2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tol J, Koopman M, Miller MC, Tibbe A, Cats
A, Creemers GJM, Vos AH, Nagtegaal ID, Terstappen LWMM and Punt
CJA: Circulating tumour cells early predict progression-free and
overall survival in advanced colorectal cancer patients treated
with chemotherapy and targeted agents. Ann Oncol. 21:1006–1012.
2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sastre J, Maestro ML, Puente J, Veganzones
S, Alfonso R, Rafael S, Gracía-Saenz JA, Vidaurreta M, Martín M,
Arroyo M, et al: Circulating tumor cells in colorectal cancer:
Correlation with clinical and pathological variables. Ann Oncol.
19:935–938. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zitt M, Zitt M, Müller HM, Dinnewitzer AJ,
Schwendinger V, Goebel G, De Vries A, Amberger A, Weiss H,
Margreiter R, et al: Disseminated tumor cells in peripheral blood:
A novel marker for therapy response in locally advanced rectal
cancer patients undergoing preoperative chemoradiation. Dis Colon
Rectum. 49:1484–1491. 2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sun W, Li G, Wan J, Zhu J, Shen W and
Zhang Z: Circulating tumor cells: A promising marker of predicting
tumor response in rectal cancer patients receiving neoadjuvant
chemo-radiation therapy. Oncotarget. 7:69507–69517. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Magni E, Botteri E, Ravenda PS, Cassatella
MC, Bertani E, Chiappa A, Luca F, Zorzino L, Bianchi PP, Adamoli L,
et al: Detection of circulating tumor cells in patients with
locally advanced rectal cancer undergoing neoadjuvant therapy
followed by curative surgery. Int J Colorectal Dis. 29:1053–1059.
2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Hinz S, Röder C, Tepel J, Hendricks A,
Schafmayer C, Becker T and Kalthoff H: Cytokeratin 20 positive
circulating tumor cells are a marker for response after neoadjuvant
chemoradiation but not for prognosis in patients with rectal
cancer. BMC Cancer. 15(953)2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Imyanitov EN and Yanus GA: Neoadjuvant
therapy: Theoretical, biological and medical consideration. Chin
Clin Oncol. 7(55)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Leary A, Cowan R, Chi D, Kehoe S and
Nankivell M: Primary surgery or neoadjuvant chemotherapy in
advanced ovarian cancer: The debate continue. Am Soc Clin Oncol
Educ Book. 35:153–162. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Inwald EC, Klinkhammer-Schalke M,
Hofstädter F, Zeman F, Koller M, Gerstenhauer M and Ortmann O:
Ki-67 is a prognostic parameter in breast cancer patients: Results
of a large population-based cohort of a cancer registry. Breast
Cancer Res Treat. 139:539–552. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lumachi F, Orlando R, Marino F, Chiara GB
and Basso SMM: Expression of p53 and Ki-67 as prognostic factors
for survival of men with colorectal cancer. Anticancer Res.
32:3965–3967. 2012.PubMed/NCBI
|
|
44
|
Ghiţă C, Vîlcea ID, Dumitrescu M, Vîlcea
AM, Mirea CS, Aşchie M and Vasilescu F: The prognostic value of the
immunohistochemical aspects of tumor suppressor genes p53, bcl-2,
PTEN and nuclear proliferative antigen Ki-67 in resected colorectal
carcinoma. Rom J Morphol Embryol. 53:549–556. 2012.PubMed/NCBI
|
|
45
|
Melling N, Kowitz CM, Simon R, Bokemeyer
C, Terracciano L, Sauter G, Izbicki JR and Marx AH: High Ki67
expression is an independent good prognostic marker in colorectal
cancer. J Clin Pathol. 69:209–214. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kiraly O, Gong G, Olipitz W, Muthupalani S
and Engelward BP: Inflammation-induced cell proliferation
potentiates DNA damage-induced mutations in vivo. PLOS Genet.
11(e1004901)2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Di Maggio FM, Minafra L, Forte GI,
Cammarata FP, Lio D, Messa C, Gilardi MC and Bravatà V: Portrait of
inflammatory response to ionizing radiation treatment. J Inflamm.
12(14)2015.PubMed/NCBI View Article : Google Scholar
|
